Filing Flows › United Therapeutics (UTHR) › Total Tyvaso revenue
United Therapeutics (UTHR) Total Tyvaso revenue by quarter
United Therapeutics' Total Tyvaso revenue was $504M in Q3 2026 (third quarter 2026), +11% from Q2 2026. Over the last 7 quarters it ranged from $453M (Q2 2026) to $504M (Q3 2026).
| Quarter | Total Tyvaso revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $504M | +11% | +5% |
| Q2 2026 | $453M | -1% | -4% |
| Q1 2026 | $458M | -1% | -2% |
| Q4 2025 | $464M | -3% | — |
| Q3 2025 | $478M | +2% | — |
| Q2 2025 | $470M | +0.7% | — |
| Q1 2025 | $466M | — | — |
Q3 2026 at a glance
United Therapeutics, Q3 2026: revenue $832M (+4% year over year), operating margin 37.0%, net earnings $259M, operating cash flow $306M. The chart follows the revenue to costs, profit and cash.
Questions
What is United Therapeutics' Total Tyvaso revenue?
United Therapeutics' Total Tyvaso revenue was $504M in Q3 2026 (third quarter 2026), +11% from Q2 2026.
How has United Therapeutics' Total Tyvaso revenue changed?
Over the last 7 quarters it ranged from $453M (Q2 2026) to $504M (Q3 2026).